Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07246278

Celecoxib in Parkinson Disease as Adjuvant Therapy

Parkinson's disease (PD) is a chronic neurodegenerative disease clinically characterized by bradykinesia, hypokinesia, rigidity, resting tremor, and postural instability. These motor manifestations are attributed to the degeneration and selective loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc), leading to a dopamine (DA) deficiency in the striatum. Neuroinflammation is considered one of the most important factors contributing critically to pathophysiology of PD . Recently, high mobility group box-1 (HMGB1) protein has been encoded as a potential inflammatory biomarker in PD

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Parkinson Disease Basal Ganglia Diseases Brain Diseases Central Nervous System Diseases Movement Disorders Nervous System Diseases Neurodegenerative Diseases Parkinsonian Disorders Synucleinopathies

Age range

50 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1 / Phase 2

Primary location

Tanta Unuversity

Tanta, 31527, Egypt

Location status: Recruiting

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥ 18 years.
  • Both male and female will be included.
  • Patients diagnosed with PD according to Unified Parkinson's Disease Rating Scale.

Exclusion criteria

  • Breast feeding
  • Patients with significant liver and kidney function abnormalities.
  • Alcohol and / or drug abusers.
  • Patients with known allergy to the study medications
  • Patients with known allergy to sulfonamides (cross hypersensitivity with celecoxib).
  • Pregnant women and women with planned pregnancy.
  • Patients who are currently using other anti-inflammatory drugs.

Treatment and study plan

Levodopa Carbidopa

Drug

Carbidopa/levodopa is the combination of the two medications carbidopa and levodopa. It is primarily used to manage the symptoms of Parkinson's disease

Celecoxib 200mg

Drug

Celecoxib, is a selective cyclooxygenase-2 inhibitor. Prostaglandins (PG) are produced from arachidonic acid by the constitutively expressed cyclooxygenase-1(COX-1)

Primary outcomes

  1. change in the Unified Parkinson's Disease Rating Scale

    Time frame: 6 months

    • Change From Baseline for Unified Parkinson's Disease Rating Scale (UPDRS) Total Score

Interested in participating?

Recruiting

Interested in participating?

Request Info

Sponsors and collaborators

Lead sponsor

Tanta University

Other

Registry information

Official study title

Evaluating Safety and Efficacy of Celecoxib in Patients With PD.

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Nov 24, 2025
Registry last updated
Dec 5, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.